accountrevenue, and Amylin Pharmaceuticals (Nasdaq: AMLN) is at 2.8 times revenue after correcting for what it pays Eli Lilly (NYSE: LLY) on Byetta. Some investors might be buying BioMarin now based on hopes for a buyout by partner Genzyme (Nasdaq: GENZ) or...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to BioMarin Is Off Track
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account